Our Company
About Us
Executive Team
Board of Directors
Scientific and Clinical Advisors
Partners
Our Science
Overview
CD6-ALCAM Pathway
Itolizumab
Publications
Pipeline
Overview
Pipeline Graphic
Clinical Trials
Patients
Therapeutic Areas
Graft-Versus-Host Disease
Uncontrolled Moderate to Severe Asthma
SLE / Lupus Nephritis
Clinical Trials
The EQUATE study
The EQUIP study
The EQUALISE Study
Investors
Investors Overview
Stock Information
News
Events & Presentations
Analyst Coverage
Financials and Filings
Corporate Governance
Investor FAQ
Contacts
Careers
Contact Us
Menu
Itolizumab Uniquely Modulates Both the Activity and Trafficking of T Effector Cells
Scroll to top
